Evaluating the effect of low-level laser versus ozone in patients with Medication-related osteonecrosis of the jaw who were treated with debridement surgery and Platelet-rich fibrin

INTERVENTION: Intervention 1: Control group: Patients receive the usual and standard debridement surgery along with PRF (Platelet‐rich fibrin). Intervention 2: Intervention group 1: In patients who have been treated with surgical debridement and PRF placement, in 10 sessions (3 days a week for 3 weeks and one session in the fourth week), (each session 2 syringes of 10 cc with a concentration of 25% in the lesion site with minimum distance of 2 cm and maximum of 4 cm from each other) will be subjected to ozone therapy with sedecal Ozone model serial number Ozt1077 made in Spain. Intervention 3: Intervention group 2: In patients who have been treated with surgical debridement and PRF placement, in 10 sessions (2 days a week for 5 weeks), (each session with a wavelength of 660 nm, 8 continuous points on the buccal surface and 8 continuous points on the lingual surface, each point will be irradiated for 15 seconds, then this process is repeated with a wavelength of 810 nm) laser therapy is performed with a THOR diode laser made in England and a power of 200 milliwatts. CONDITION: Condition 1: Osteonecrosis. Condition 2: Pain in jaw. Condition 3: Soft tissue dehiscence. ; Osteonecrosis due to drugs ; Disease of jaws, unspecified ; Soft tissue disorder, unspecified K10.9 M79.9 M87.1 PRIMARY OUTCOME: Amount of jaw pain in the specified time period. Timepoint: 1, 3, 6 and 12 months after the intervention. Method of measurement: Visual Analogue Scale (VAS) in checklist. Soft tissue healing. Timepoint: 1, 3, 6 and 12 months after the intervention. Method of measurement: Appropriate soft tissue healing was defined when no dehiscence occurred. SECONDARY OUTCOME: Infection. Timepoint: 1, 3, 6 and 12 months after the intervention. Method of measurement: Any sign of pus or fistula tract in treatment area. INCLUSION CRITERIA: All patients with Medication‐related osteonecrosis of the jaw, MRONJ stage 2, with pain and pus discharge No history of previous MRONJ treatment Absence of pathological fracture during study entry